APOE4通过线粒体功能障碍加剧了葡萄糖皮质激素应激激素诱导的病理
Qing Yu1, Fang Du1,2, Jeffrey Goodman2
1Department of Pathology and Cell Biology, Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.
bioRxiv : the preprint server for biology
|February 20, 2025
概括
APOE4基因变体通过引起线粒体功能障碍,在海马体中加剧了压力诱导的病理. 准线粒体透性过渡孔可能为阿尔茨海默病提供治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,具有遗传和环境风险因素.
- 在阿波利波蛋白E4 (APOE4) 的等位基因是AD的主要遗传风险因素.
- 慢性压力是一个重要的环境风险因素,APOE4可能会增加对其影响的脆弱性.
研究的目的:
- 研究APOE4如何影响海马中神经元对慢性压力的脆弱性,特别是葡萄糖皮质类药物.
- 探索APOE4介导的压力敏感性的潜在机制.
主要方法:
- 利用人性化的APOE4和APOE3敲击小鼠模型和原发海马神经元.
- 进行了体内和体外实验,以评估压力/糖皮质激素的影响.
- 检查了病理,线粒体功能,葡萄糖皮质体受体激活和线粒体透性过渡孔 (MPTP) 开放.
主要成果:
- 与在压力条件下的APOE3小鼠相比,APOE4小鼠显示出恶化的tau病理 (积累,高酸化,扩散).
- APOE4小鼠表现出线粒体功能障碍和海马体中葡萄糖皮质体受体激活的增加.
- 在APOE4小鼠中,MPTP的开放被确定为线粒体功能障碍和病理的驱动因素.
- 药理上抑制MPTP开放,可以防止APOE4介导的线粒体损伤,病理和突触损失.
结论:
- APOE4对葡萄糖皮质类药物的敏感性增加,导致病原发生加速.
- 由MPTP开放驱动的线粒体功能障碍是APOE4介导的压力脆弱性的关键机制.
- 准MPTP是缓解APOE4载体AD的潜在治疗途径.
相关概念视频
Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150


